News

Savara Pharmaceuticals announced that it has finished with the steps necessary to fully acquire Serendex Pharmaceuticals, strengthening its position as a developer of therapies for rare respiratory diseases. Savara’s pipeline of products now includes these three, according to a press release: Alveodex, a proprietary nebulized formulation of Factor VIIa (recombinant human FVIIa),…

Pharmaxis announced that it has completed recruiting adult patients with cystic fibrosis (CF) for its large and potentially pivotal  Phase 3 clinical trial evaluating Bronchitol (mannitol) as an inhaled treatment.  The company expects to report results in the second quarter of 2017. Based on those results, the company will apply for U.S. Food and Drug…

Interleukin-22 is known to protect against respiratory pathogens through its ability to mediate mucosal immunity and tissue regeneration. But new research into its possible use against Pseudomonas aeruginosa, a main cystic fibrosis pathogen, found that IL-22 disappointed — with scientists reporting IL-22 failed to protect a mice model from such infection and even seem to…

Increasing the pH balance of the acidic lung surface liquid found in cystic fibrosis (CF) patients, using an inhaled alkaline buffer, helps to kill bacteria in the airways, research from the University of Iowa Carver College of Medicine found. The study, “Repurposing tromethamine as inhaled therapy to treat…

Adult patients with cystic fibrosis (CF) show improvements in lung function decline when treated with a high dosage of tiotropium bromide taken over a long term (24 months). Patients with cystic fibrosis often succumb to chronic lung disease, the leading cause of death among cystic fibrosis patients. Chronic lung disease is often…

Vertex Pharmaceuticals and Moderna Therapeutics recently entered a three-year research partnership and licensing agreement to discover and develop the messenger ribonucleic acid, trademarked as (mRNA) Therapeutics, for the treatment of cystic fibrosis (CF). The alliance between the two companies will center on usimg mRNA drugs to treat the CF  at its core, by…

Nivalis Therapeutics Inc. recently announced that they finished enrolling participants for a Phase 2 clinical trial testing their lead compound N91115 for the treatment of cystic fibrosis (CF).

A recently published study proposes that viruses capable of infecting bacteria, called bacteriophages, may be responsible for accelerating the evolution and increasing the impact of Pseudomonas aeruginosa, a bacterial species that causes chronic lung infections in cystic fibrosis (CF) patients.   ‘Temperate phages both mediate and drive…

A recent study confirmed that different structure and composition of airway microbiota (symbiotic helpful and harmful microrganisms) exist in cystic fibrosis (CF) patients with stable or declining lung function; and shed new light on the fact that microbiota in stable lungs provides higher resilience to bacteria than lungs in severe function decline.

Because some cystic Fibrosis (CF) clinics often fail to follow published guidelines for the screening and care of diabetes in CF patients, but self-implemented ways can produce better patient outcomes, a recent study suggests that optimal care can differ from recommendations. CF-related diabetes is an increasingly common complication in CF patients, resulting in substantial…